MRNA cancer shots: new hope or hype?
NCT ID NCT06880549
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial tests two experimental mRNA therapies (mRNA-4106 and mRNA-4200) in 42 people with advanced solid tumors like melanoma, lung, or liver cancer. Some participants receive the mRNA therapy alone, others get it combined with the immunotherapy drug pembrolizumab. The main goal is to check safety and find the right dose, not yet to prove the treatment works.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
mRNA-4106 and mRNA-4200 (mRNA-based therapies) with or without pembrolizumab (immunotherapy)
What this could lead to
If successful, this could point toward a new treatment option for advanced solid tumors that have not responded to other therapies.
What could go wrong
This is a very early (Phase 1) trial with only 42 people, so it is primarily checking safety and dosing. The treatments may not shrink tumors or work for everyone, and side effects are unknown.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GASTRIC CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
START Midwest
Grand Rapids, Michigan, 49546, United States
-
START Mountain Region
West Valley City, Utah, 84119, United States
-
START San Antonio
San Antonio, Texas, 78229, United States